New data from digital marketing agency Sagapixel reveals that public interest in the term “GLP-1” has officially surpassed search volume for “Ozempic” — marking a fundamental shift in how patients ...

Over two percent of adult patients now take a GLP-1 drug to treat overweight or obesity, according to newly released FAIR ...

The average representation of GLP-1 drugs used for weight loss in total annual claims was 10.5% for 2025, an increase over ...

In 2024, 4% of U.S. adults were prescribed a GLP-1 therapy — a 363.7% increase from 0.9% in 2019, according to a Fair Health analysis of more than 51 billion commercial claim records.  Fair Health ...

Veru's pivot with enobosarm: groundbreaking Phase 2b results enhance GLP-1 therapy outcomes. A positive launch could yield ...

As Australia faces a turning point in obesity management, researchers from Monash University have contributed new insights ...

For people trying to quit smoking, use of a GLP-1 receptor agonist may help prevent weight gain, a common barrier to quitting ...

David Kessler has lost more than 60 pounds on weight-loss drugs and believes they can change the trajectory of chronic ...

GLP-1 agonists may help reduce acetazolamide dosage in patients with idiopathic intracranial hypertension without changing clinical outcome.

And GLP-1 agonists were associated with an 8% lower mortality risk as well (HR 0.92, 95% CI 0.87-0.97), according to findings ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

If you're one of the millions of Americans who have used or thought about using GLP-1 weight-loss drugs, it’s important to ...